From a therapeutic perspective, the development of anti-CD303 antibodies and antibody-drug conjugates (ADCs) is likely to greatly improve treatment outcomes for BPDCN. Here, CLEC4C is linked to CD4+/CD56+ hematodermic neoplasm.